Analyst Price Target is $5.00
▲ +259.71% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Trevena in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 259.71% upside from the last price of $1.39.
Current Consensus is
Hold
The current consensus among 1 polled investment analysts is to hold stock in Trevena. This rating has held steady since November 2024, when it changed from a Buy consensus rating.
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.
Read More